WSTAM
AVDL

Wilbanks Smith & Thomas Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-240
Closed -$1K – 424
2018
Q3 		$1K Buy
+240
New +$1.3K ﹤0.01% 1488

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's AVDL Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2018, closing a stake of 240 shares — an estimated $1K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in AVDL in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 59 funds tracked by Wall St. Rank hold AVDL as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Avadel Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 240 Avadel Pharmaceuticals shares in Q4 2018, an estimated $1K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Avadel Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Avadel Pharmaceuticals position peaked at $1K in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.